Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial

202154 citationsJournal Articlehybrid Open Access

Authors

Geoff Bellingan · UCL Biomedical Research Centre

F.J. Jacono · Case Western Reserve University

Jonathan Bannard‐Smith · Manchester University NHS Foundation Trust

David Brealey · University College London

Nuala J. Meyer · University of Pennsylvania

David Thickett · University Hospitals Birmingham NHS Foundation Trust

Duncan Young

Abstract

Multipotent adult progenitor cells were safe and well tolerated in ARDS. The clinical outcomes warrant larger trials to evaluate the therapeutic efficacy and optimal patient population.

Topics & Keywords

Neonatal Respiratory Health Research Respiratory Support and Mechanisms Mesenchymal stem cell research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Intensive Care Medicine

Volume 48, Issue 1, pp. 36-44

DOI: 10.1007/s00134-021-06570-4

Field-Weighted Citation Impact: 7.49